News|Articles|April 28, 2025

This Week on NeurologyLive® — April 28, 2025

Listen

0:00 / 0:00

Key Takeaways

NeurologyLive will cover a variety of hot topics, offering in-depth analyses and expert interviews on recent developments in neurology.
The platform aims to keep professionals informed about the latest research findings and pressing issues in the field.
Readers are encouraged to explore the website for additional content, as the coverage extends beyond the highlighted topics.

Here's some of what is coming soon to NeurologyLive® this week.

Every week, the NeurologyLive^® staff prepares this preview of what to expect from our coverage. This week on NeurologyLive, there are a number of hot topics that we will be posting on the website. As always, our weekly coverage extends beyond just these topics, so make sure to check out the rest of the site!

Click through the slides below to see what you can expect from our team this week. Click any slide to check out the content.

—————————————————

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related to this article

September 30th, 2026

NeuroVoices: James Winkley, MD, on Analyzing Phase 3 PREVAIL Trial of Gefurulimab

The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.

September 28th, 2026

FDA Approves Tavapadon for the Treatment of Parkinson Disease

FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.

September 28th, 2026

This Week on NeurologyLive® — September 28, 2026

Here's some of what is coming soon to NeurologyLive® this week.

September 23rd, 2026

Real-World Study Supports Peroneal Nerve Stimulation for Restless Legs Syndrome Symptoms

Tonic motor activation therapy was associated with reductions in RLS severity, along with tolerable reductions in dopamine agonist dosing, in adults with medication-refractory RLS.

September 21st, 2026

This Week on NeurologyLive® — September 21, 2026

Here's some of what is coming soon to NeurologyLive® this week.

September 30th, 2026

Vanda to Pursue sNDA for Tasimelteon in Delayed Sleep-Wake Phase Disorder After Positive Phase 3 Readout

In a pivotal phase 3 study, once-daily tasimelteon 20 mg shifted sleep onset 37.1 minutes earlier than placebo in adults with delayed sleep-wake phase disorder.

September 30th, 2026

Single Infusion of Rese-Cel Yields Meaningful Responses Off Immunomodulators in Phase 1/2 RESET-MG Trial

Findings from the phase 1/2 RESET-MG trial, presented at AANEM 2026, showed that 10 of 13 patients with refractory generalized myasthenia gravis had clinically meaningful MG-ADL improvements after a single infusion of rese-cel.

September 30th, 2026

Episode 176: BBP-418 and the Changing Treatment Landscape of LGMD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Katherine Matthews, MD. [LISTEN TIME: 17 minutes]

This Week on NeurologyLive® — April 28, 2025

Key Takeaways

Related to this article

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Approves Tavapadon for the Treatment of Parkinson Disease

FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS

New Phase 3 Trials to Test Empasiprubart Against Placebo, IVIG in CIDP

Inebilizumab Shows Durable Benefit in MuSK+ Generalized Myasthenia Gravis at AANEM 2026

NeuroVoices: James Winkley, MD, on Analyzing Phase 3 PREVAIL Trial of Gefurulimab